Franklin Resources Inc. Has $3.86 Million Stock Position in Qiagen (NYSE:QGEN)

Franklin Resources Inc. trimmed its holdings in shares of Qiagen (NYSE:QGEN) by 33.3% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 87,470 shares of the company’s stock after selling 43,616 shares during the period. Franklin Resources Inc.’s holdings in Qiagen were worth $3,857,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. GAMMA Investing LLC raised its holdings in shares of Qiagen by 806.5% during the third quarter. GAMMA Investing LLC now owns 562 shares of the company’s stock valued at $26,000 after purchasing an additional 500 shares during the period. Toronto Dominion Bank acquired a new position in Qiagen during the 2nd quarter worth approximately $27,000. Massmutual Trust Co. FSB ADV raised its stake in Qiagen by 39.8% during the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock worth $39,000 after buying an additional 243 shares during the period. Wilmington Savings Fund Society FSB bought a new position in Qiagen in the third quarter worth approximately $53,000. Finally, Headlands Technologies LLC grew its stake in Qiagen by 396.6% in the second quarter. Headlands Technologies LLC now owns 2,741 shares of the company’s stock valued at $113,000 after acquiring an additional 2,189 shares during the period. Institutional investors and hedge funds own 70.00% of the company’s stock.

Qiagen Stock Up 0.5 %

QGEN opened at $45.06 on Wednesday. The company has a quick ratio of 1.89, a current ratio of 2.17 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $10.28 billion, a price-to-earnings ratio of 115.54, a PEG ratio of 3.52 and a beta of 0.35. The firm has a 50 day moving average price of $43.36 and a 200-day moving average price of $43.76. Qiagen has a twelve month low of $39.03 and a twelve month high of $47.44.

Analyst Ratings Changes

A number of brokerages recently issued reports on QGEN. HSBC cut Qiagen from a “buy” rating to a “hold” rating and set a $49.00 target price on the stock. in a report on Thursday, October 17th. Jefferies Financial Group restated a “buy” rating and issued a $54.00 target price (up previously from $42.00) on shares of Qiagen in a report on Tuesday, December 10th. Finally, Hsbc Global Res upgraded Qiagen to a “hold” rating in a research note on Thursday, October 17th. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $51.88.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.